Toxicity and survival associated with IV/IP chemotherapy following neoadjuvant chemotherapy and interval debulking surgery for epithelial ovarian, fallopian tube, and primary peritoneal cancer

被引：0
|
作者：
Rios-Doria, E. [1 ]
Pezzillo, M. [1 ]
Ulm, M. A. [2 ]
Tillmanns, T. [2 ]
机构：
[1] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA
[2] Univ Tennessee, West Canc Ctr, Memphis, TN USA
来源：
GYNECOLOGIC ONCOLOGY | 2020年 / 159卷
关键词：
D O I：
10.1016/j.ygyno.2020.05.157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
269
引用
收藏
页码：127 / 128
页数：2
相关论文
共 50 条
  • [31] Should neoadjuvant chemotherapy be preferred to an alternative treatment for advanced ovarian cancer: Comparison of neoadjuvant chemotherapy followed by interval debulking surgery and primary debulking surgery in patients with advanced ovarian cancer
    Liu, J.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 176 - 176
  • [32] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Ce Bian
    Kui Yao
    Li Li
    Tao Yi
    Xia Zhao
    Archives of Gynecology and Obstetrics, 2016, 293 : 163 - 168
  • [33] Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
    Liu, Ying L.
    Filippova, Olga T.
    Zhou, Qin
    Iasonos, Alexia
    Chi, Dennis S.
    Zivanovic, Oliver
    Sonoda, Yukio
    Gardner, Ginger J.
    Broach, Vance A.
    O'Cearbhaill, Roisin E.
    Konner, Jason A.
    Aghajanian, Carol
    Roche, Kara Long
    Tew, William P.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (01)
  • [34] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Bian, Ce
    Yao, Kui
    Li, Li
    Yi, Tao
    Zhao, Xia
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 293 (01) : 163 - 168
  • [35] Postoperative survival analysis of laparotomy versus robotic interval debulking in epithelial ovarian cancer patients following neoadjuvant chemotherapy
    Paraghamian, S. E.
    Staley, A.
    Tucker, K.
    Zhang, Y.
    Wang, M.
    Clark, L. H.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 148 - 148
  • [36] Cost-effectiveness of hyperthermic intraperitoneal chemotherapy HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy
    Lim, Stephanie L.
    Havrilesky, Laura J.
    Habib, Ashraf S.
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2019, 153 (02) : 376 - 380
  • [37] COST-EFFECTIVENESS OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) AT INTERVAL DEBULKING OF EPITHELIAL OVARIAN CANCER FOLLOWING NEOADJUVANT CHEMOTHERAPY
    Lim, S.
    Havrilesky, L.
    Cohn, D.
    Habib, A.
    Secord, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 627 - 627
  • [38] Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection
    Gill, Sarah E.
    McGree, Michaela E.
    Weaver, Amy L.
    Cliby, William A.
    Langstraat, Carrie L.
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 266 - 273
  • [39] Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
    Iura, Ayaka
    Takita, Morihito
    Kawano, Aiko
    Imai, Kazuaki
    Konnai, Katsuyuki
    Onose, Ryo
    Kato, Hisamori
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2018, 29 (05)
  • [40] Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009
    Tiersten, Amy D.
    Liu, P. Y.
    Smith, Harriet O.
    Wilczynski, Sharon R.
    Robinson, William R., III
    Markman, Maurie
    Alberts, David S.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (03) : 444 - 449
12345